trial

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

NCTId NCT07288567
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 166 (estimated)
Sponsored by Bristol-Myers
Primary completion 2029-12-18
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
166 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2026-01-29
Primary completion
2029-12-18
Eligibility
ALL · 13 Years · 17 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Bristol-MyersLead Sponsor

Sites

44 total
Anaheim, United StatesChino, United StatesCulver City, United StatesRedlands, United StatesSan Francisco, United StatesHollywood, United StatesOrlando, United StatesAtlanta, United StatesLawrenceville, United StatesStone Mountain, United StatesChicago, United StatesBoston, United States

Linked catalysts

1
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizo — primary completion2029-12-18

Facts & assertions

4 sourced
Enrollment
166
Phase
PHASE3
Primary Completion Date
2029-12-18
Status
RECRUITING
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Bristol-Myers
company
indication
Schizophrenia
indication
Schizophrenia
indication